Is Ascendis Pharma A/S (ASND) a risky stock?
As of July 27, 2026, Clavix grades Ascendis Pharma A/S (ASND) C for risk, a composite score of 55 out of 100 on an A+ to F scale, which puts ASND in the "average" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 27, 2026. Clavix regrades every trading day.
The five risk dimensions behind ASND's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ASND scores on each, as of July 27, 2026.
What's moving ASND's risk right now
Company-specific signals Clavix flags behind ASND's current grade, drawn from recent news and filings as of July 27, 2026.
A notable institutional investor cut its ASND position because of ongoing litigation, which could pressure the stock and signal broader institutional caution about the legal situation.
ASND appeared on MarketBeat's list of growth stocks to track on July 22, 24, and 26, which may draw some short-term retail attention but isn't a formal rating or fundamental catalyst.
Recent ASND news
The latest headlines Clavix ingested for Ascendis Pharma A/S, newest first. These feed the news-sentiment dimension of ASND's grade.
What a C grade means
On the Clavix A+ to F scale, ASND's composite of 55 falls in the C band (50–64), read as "average." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ASND or any security. Grades are risk indicators, not predictions of return. Data may be delayed.